AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.

Abstract

Persistent infection with oncogenic human papillomavirus (HPV)-16 and -18 accounts for over 70% of all cases of cervical cancer. Vaccination against these HPV types has become a reality. This article discusses the latest data available for Cervarix (GlaxoSmithKline Biologicals), an AS04-adjuvanted HPV-16/18 vaccine, and considers immunological factors… (More)
DOI: 10.1586/14760584.7.10.1465

Topics

Cite this paper

@article{Schwarz2008AS04adjuvantedHP, title={AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention.}, author={Tino F Schwarz}, journal={Expert review of vaccines}, year={2008}, volume={7 10}, pages={1465-73} }